30 closest matches · ranked by relevance
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Pulmonary Embolism · Acute Pulmonary Embolism · Sub-massive Pulmonary Embolism
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio
Massive Pulmonary Embolism
Primary: Death From All Causes — 3; 4 Participants — p=<0.05
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
Submassive Pulmonary Embolism
Primary: Number of Participants With Major Bleeding Events — 1; 0; 0; 0 participants
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
Cardiovascular Diseases
Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Pulmonary Embolism · Thrombotic Disease
Primary: Number of Participants Experiencing Adjudicated Clinically Relevant Bleeding Events Following Intravenous Infusion of DS-1040b or Placebo in Addition to Standard of Care…
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Subjects With Major Adverse Events — 24; 964 Participants
Pulmonary Embolism
Primary: Right Ventricle/Left Ventricle (RV:LV) Ratio — 0.43 Change in RV/LV Diameter Ratio
Pulmonary Embolism · Pulmonary Thromboembolism
Primary: Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio — 52693; 10509 Number of Wins for the group
Pulmonary Embolism · Acute Pulmonary Embolism
Primary: Change in Right Ventricle to Left Ventricle (RV/LV) Ratio Between Baseline and 48 Hours Post-procedure Assessed by Computed Tomography Angiography (CTA) — -0.45 ratio
Submassive Pulmonary Embolism
Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio
Pulmonary Embolism
Primary: Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement — 0; 136 percent change
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
Pulmonary Embolism
Primary: Number of Participants With Normal Right Ventricular (RV) Function and Viability — 9; 5 Participants
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
Pulmonary Embolism
Primary: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal…
Chronic Thromboembolic Pulmonary Hypertension
Primary: Concentration of Matrix Metalloproteinase 2 and 9 Enzymes — 89289.89; 86548.72; 205707.83; 152911.57 ng/ml — p=<0.05
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
Pulmonary Embolism
Primary: Primary Safety Endpoint (Composite): Incidence of Adjudicated Serious Adverse Events (SAE) — 0; 50 Participants
Pulmonary Embolism
Primary: Safety: Number of Participants With Major Bleeding Events — 1 Participants
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56